精东影业

笔辞蝉颈迟颈辞苍(蝉):听听Professor听鈥�

Academic Department:听Biological Sciences

颁辞苍迟补肠迟:听dwu@cau.edu 鈥嬧��鈥�鈥�
Office Location:听Thomas Cole Research听Center听鈥嬧��
Office Telephone:听404-880-6337

Education:

Ph.D. in Biochemistry Peking University Beijing, China鈥�

听

Research Interests:鈥�

• Dr. Wu鈥檚 research interest includes the biology of tumor metastasis and the development of new听prevention and treatment for prostate cancer, pancreatic cancer and osteosarcoma.听鈥�
• His studies have identified several new therapeutic targets and developed small-molecule听inhibitors of EED-EZH2 interaction and SCF complexes.听鈥�
• Several non-cancerous drugs have shown promising efficacy in preclinical models of prostate听cancer and pancreatic cancer.听鈥�
• A nutraceutical formulation,听ProFine, demonstrated favorable efficacy and safety in treating听prostate cancer.听鈥�
• Dr. Wu鈥檚 current efforts focus on the translation and commercialization of laboratory research听into clinical use for the treatment of advanced cancer.

笔耻产濒颈肠补迟颈辞苍蝉:听

• Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D. Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models. British Journal of Cancer, doi: 10.1038/s41416-023-02359-y, 2023.
• Bai L, Li X, Yang Y, Zhao R, White EZ, Danaher A, Bowen NJ, Hinton CV, Cook N, Li D, Wu AY, Qui M, Du Y, Fu H, Kucuk O, Wu D. Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models. Translational Oncology, 34:101707, 2023.
• Zhao R, Ma X, Bai L, Li X, Mamouni K, Yang Y, Liu H, Danaher A, Cook N, Kucuk O, Hodges RS, Gera L, Wu D. Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. Neoplasia, 23:1261-1274, 2021.
• Wu D, Osunkoya AO, Kucuk O. Epithelial protein lost in neoplasm (EPLIN) and prostate cancer: lessons learned from the ARCaP model. American Journal of Clinical and Experimental Urology, 9:264-276, 2021.
• Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D. Allosteric EED inhibitor suppresses EZH2 signaling and overcomes chemoresistance in prostate cancer. Theranostics, 11:6873-6890, 2021.
• Cook N, Chen J, Zhou J, Wu D. Embryonic ectoderm development (EED) as a novel target for cancer treatment. Current Topic in Medicinal Chemistry, 21:2771-2777, 2021.
• Chen Y, Li X, Mamouni K, Yang Y, Danaher A, White J, Liu H, Kucuk O, Gera L, Wu D. Novel small molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer. Prostate, 80:993-1005, 2020.听
• Bai L, Li X, Ma X, Zhao R, Wu D. In vitro effect and mechanism of action of ergot alkaloid dihydroergocristine in chemoresistant prostate cancer cells. Anticancer Research, 40:6051-6062, 2020.
• Chen Y, Gera L, Zhang S, Li X, Yang Y, Mamouni K, Wu AY, Liu HY, Kucuk O, Wu D. Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models. Cancer Letters, 446: 62-72, 2019.
• Mamouni K, Zhang S, Li X, Chen Y, Yang Y, Kim J, Bartlett MG, Coleman IM, Nelson PS, Kucuk O, Wu D. A novel flavonoid composition targets androgen receptor signaling and inhibits prostate cancer growth in preclinical models. Neoplasia, 20:789-799, 2018.
• Yang Y, Mamouni K, Li X, Chen Y, Kavuri S, Du Y, Fu H, Kucuk O, Wu D. Repositioning dopamine D2 receptor agonist bromocriptine to enhance docetaxel chemotherapy and treat bone metastatic prostate cancer. Molecular Cancer Therapeutics, 17: 1859-1870, 2018.

Click听to access publications in PubMed.